Migraine management goes beyond acute symptom control and may also include preventive strategies for patients with a significant disease burden. Although triptans remain the recommended first-line treatment for acute migraine, more than 30% of patients cannot use them or do not achieve sufficient relief. Calcitonin gene-related peptide (CGRP) receptor antagonists have therefore emerged as a promising alternative treatment option.
Autoren
- Aneta Dehn
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack
Comprehensive diagnostic testing can reduce the risk of stroke
- Malignant Tumors of the Clavicle
Surgical Challenges and Recurrence Patterns
- Chronic hand eczema: common, long-lasting, and distressing
Non-steroidal anti-inflammatory treatment options are essential for long-term management
- Alcohol Consumption While Taking Semaglutide
Withdrawal Symptoms Thanks to GLP-1 RA?
- Why Echocardiography Has Redefined the Clinical Picture